Abstract
Patient-reported outcomes in the OlympiA trial show that olaparib was well tolerated compared with placebo.
- Title
- Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer
- Creators
- Patricia A. Ganz - University of California, Los AngelesHanna Bandos - NRG OncologyTanja Španić - Europa DonnaSue Friedman - Facing Our Risk of Cancer EmpoweredVolkmar Müller - Universität HamburgSherko Kuemmel - Kliniken Essen-MitteSuzette Delaloge - Institut Gustave RoussyEtienne Brain - Institut CurieMasakazu Toi - Kyoto University HospitalHideko Yamauchi - St. Luke's International HospitalEduardo-M. de Dueñas - Consorcio Hospitalario Provincial de CastellónAnne Armstrong - The Christie HospitalSeock-Ah Im - Seoul National University HospitalChuan-gui Song - Union HospitalHong Zheng - Sichuan UniversityTomasz Sarosiek - Luxmed Onkologia, WarsawPriyanka Sharma - University of Kansas Medical CenterCuizhi Geng - Hebei Medical UniversityPeifen Fu - First Affiliated Hospital Zhejiang UniversityKerstin Rhiem - University Hospital CologneHeike Frauchiger-Heuer - Breast CenterPauline Wimberger - University Hospital Carl Gustav CarusDaphné t'Kint de Roodenbeke - Université Libre de BruxellesNing Liao - Guangdong Provincial People's HospitalAnnabel Goodwin - The University of SydneyCamille Chakiba-Brugère - Institut BergoniéMichael Friedlander - Prince of Wales HospitalKeun Seok Lee - National Cancer CenterSylvie Giacchetti - Hôpital Saint-LouisToshimi Takano - The Cancer Institute HospitalFernando Henao-Carrasco - GEICAM – Spanish Breast Cancer GroupShamsuddin Virani - Aurora Health CareFrances Valdes-Albini - University of MiamiSusan M. Domchek - University of PennsylvaniaCharles Bane - Dayton Physicians NetworkEdward C. McCarron - MedStar Franklin Square Medical CenterMonica Mita - Cedars-Sinai Medical CenterGiovanna Rossi - Breast International GroupPriya Rastogi - UPMC Hillman Cancer CenterAnitra Fielding - AstraZenecaRichard D. Gelber - Dana-Farber Cancer InstituteElsemieke D. Scheepers - Frontier AgricultureDavid Cameron - University of EdinburghJudy Garber - Dana-Farber/Harvard Cancer CenterCharles E. Geyer - UPMC Hillman Cancer CenterAndrew N.J. Tutt - The Institute of Cancer Research London, London, Kings College London, London
- Publication Details
- Journal of clinical oncology, Vol.42(11), pp.1288-1300
- Publisher
- Wolters Kluwer Health
- Number of pages
- 13
- Academic Unit
- Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
- Language
- English; Japanese
- Resource Type
- Journal article
- PMID
- 38301187
- Record Identifier
- 991032796103502976